Target-dependent methods, using a combination of biophysical techniques, chemoinformatics and medicinal chemistry with versatile screening platforms, are used to find promising hits.
- A priori Selection:
A priori selection of molecules based on publications, virtual screening (structure-based drug design, ligand-based drug design) and medicinal chemistry knowledge, followed by binding confirmation.
- Fragment Screening
The NovA-Frag library of 1000 fragments can be screened on different biophysical platforms such as NMR or native MS. Hits can be confirmed by an orthogonal assay.